You are here:
Company

MimeCure

Back to overview

MimeCure is an innovative pharmaceutical start-up based on pioneering research conducted at the Groningen Research Institute of Pharmacy at the University of Groningen (NL). The discovery of molecules with potential therapeutic effects on COPD is the culmination of several years of intensive research at the university. Thanks to close collaboration between leading scientists from different disciplines, the research team has made significant progress in the development of new drugs for COPD.

Their work has led to an efficient research pipeline, from preclinical screening technologies to advanced formulation of bio-inspired molecules. Recognising the potential of these discoveries, they decided to separate from the university and founded MimeCure in April 2024 to transform these innovations into clinical solutions for COPD patients.

MimeCure belongs to the fund:

Pharma Connect Capital">

Investment fund Pharma Connect Capital (PCC) invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects...

View all the funds from the IFG

Arches Capital is a fast growing group of business angels that is bridging the gap between Venture Capitalist (VCs) and...
Lumo Labs creates opportunities for impact-driven ventures in emerging technologies....